Anoikis-Related Genes Signature Contributes to Predicting Prognosis and Response to Immunotherapy in Lung Squamous Cell Carcinoma
A cancer gene signature combined with clinical information may help doctors choose which lung cancer patients benefit most from immunotherapy.
Bioinformatic analysis identified an anoikis-resistance gene signature (S100A7, S100A8, SPP1) associated with immune suppression and prognosis in lung squamous cell carcinoma. A nomogram integrating this signature with clinical variables demonstrated moderate performance for overall survival prediction and may inform personalized immunotherapy selection.
What the study was
- Study design
- Computational/bioinformatics study; retrospective transcriptomic analysis
- Population
- Lung squamous cell carcinoma (LUSC) patients (TCGA/GEO datasets)
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Medical Science Monitor
Why it surfaced
Bioinformatics-derived signature for immunotherapy response prediction in LUSC; moderate prognostic utility acknowledged; needs prospective clinical validation.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.